Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.61
Industry P/E
--
Debt to Equity
0.05
ROE
-17.03 %
ROCE
-1253.1 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-50.09 Mln
EBITDA
$-68.75 Mln
Net Profit
$-69.17 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc (CNSP)
| -86.38 | -73.72 | -84.93 | -99.84 | -96.96 | -91.91 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc (CNSP)
| -99.80 | -47.08 | -88.60 | -60.56 | -54.94 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed... Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas. Address: 2100 West Loop South, Houston, TX, United States, 77027 Read more
CEO, President & Director
Mr. John Michael Climaco Esq., J.D.
CEO, President & Director
Mr. John Michael Climaco Esq., J.D.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cns Pharmaceuticals Inc (CNSP) stood at $ 9 Mln as on 31-Dec-24
The share price of Cns Pharmaceuticals Inc (CNSP) is $0.82 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Cns Pharmaceuticals Inc (CNSP) has given a return of -96.96% in the last 3 years.
Cns Pharmaceuticals Inc (CNSP) has a market capitalisation of $ 3 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cns Pharmaceuticals Inc (CNSP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cns Pharmaceuticals Inc (CNSP) and enter the required number of quantities and click on buy to purchase the shares of Cns Pharmaceuticals Inc (CNSP).
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas. Address: 2100 West Loop South, Houston, TX, United States, 77027
The CEO & director of Mr. John Michael Climaco Esq., J.D.. is Cns Pharmaceuticals Inc (CNSP), and CFO & Sr. VP is Mr. John Michael Climaco Esq., J.D..
There is no promoter pledging in Cns Pharmaceuticals Inc (CNSP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Cns Pharmaceuticals Inc (CNSP) | Ratios |
|---|---|
|
Return on equity(%)
|
-1703.39
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cns Pharmaceuticals Inc (CNSP) was $0 Mln.
$0.00
(
